-
Dr. Jie Jin: the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)
The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both…
-
Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023
From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology…
-
Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes
Dr. Komrokji delved into the revised classifications for Myelodysplastic Syndromes (MDS) unveiled at the International Congress. The discussion contrasted the 2016 and 2022 editions, spotlighting new molecularly defined subcategories, such as SF3B1 MDS and biallelic p53, alongside morphological distinctions like MDS with increased blast types, hypoplastic MDS, and MDS with fibrosis. Dr. Komrokji’s insights underscored…
-
Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia
Abstract: Dr. Nigel Russell provides insights into the recent developments in the treatment landscape of Acute Myeloid Leukemia (AML). The discussion encompasses the combination of FLT3 mutation inhibitors with intensive chemotherapy, emphasizing the effectiveness and safety demonstrated by the combination of midostaurin with gemtuzumab ozogamicin. The presentation explores emerging FLT3 inhibitors like quizartinib and their…
-
Dr. Niels Van de Donk: Navigating the Horizon of CAR-T Treatment for RRMM
Editor’s Note: In this captivating interview, Dr. Niels Van de Donk offers an extensive exploration of the recent advancements and future prospects in Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory multiple myeloma (RRMM). Dr. Donk’s insights, ranging from the dynamic landscape of CAR-T targets to pivotal studies like MAJESTEC-1, provide a comprehensive overview of…
-
Professor SiZhou Feng : The Application of mNGS in Hematological Infections and the Optimization of Empirical Treatment Plans for Neutropenia-Associated Fever
Editor’s Note: At the recently held Fourth China Hematology Development Conference, the “Chinese Expert Consensus on the Application of Metagenomic Next-Generation Sequencing (mNGS) in the Diagnosis of Infectious Pathogens in…
-
Multidisciplinary Perspective: Professor MingGui Wang Shares Insights on the Application of mNGS in Blood Disease Infection Detection and Progress in Global CRO New Drug Treatment
Infectious Disease Frontline: The “Chinese Expert Consensus on the Application of Metagenomic Next-Generation Sequencing Technology in the Diagnosis of Pathogens in Blood Disease Infections” has been published. How do you view…
Connecting Medical Expertise through Media
